Chromosome 4 hyperploidy represents an early genetic aberration in premalignant Barrett's oesophagus

Gut

Volumn 52, Issue 5, 2003, Pages 623-628

  Doak, S H ^a   Jenkins, G J S ^a   Parry, E M ^a   D'Souza, F R ^b   Griffiths, A P ^b   Toffazal, N ^b   Shah, V ^c   Baxter, J N ^b   Parry, J M ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b MORRISTON HOSPITAL   (United Kingdom)

^c SINGLETON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P16;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CARCINOGENESIS; CHROMOSOME 20; CHROMOSOME 4; CHROMOSOME 8; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CORRELATION ANALYSIS; CYTOLOGY; DISEASE COURSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE IDENTIFICATION; GENE LOCUS; GENETIC STABILITY; HUMAN; MALE; MALIGNANT TRANSFORMATION; PLOIDY; PRECANCER; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; Y CHROMOSOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANEUPLOIDY; BARRETT ESOPHAGUS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 20; CHROMOSOMES, HUMAN, PAIR 4; CHROMOSOMES, HUMAN, PAIR 8; CHROMOSOMES, HUMAN, Y; ESOPHAGEAL NEOPLASMS; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MIDDLE AGED; PRECANCEROUS CONDITIONS;

EID: 0037624671     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.52.5.623     Document Type: Article

References (34)

1. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
2. Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 1998;93:1028-31.
3. Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-53.
4. Conio M, Cameron AJ, Romero Y, et al. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut 2001;48:304-9.
5. Solaymani Dodaran M, Silcocks PB, Logan RFA. Continuing rise in incidence of oesophageal adenocarcinoma in England and Wales. Gut 2001;48(suppl 1):110.
6. Farrow DC, Vaughan TL. Determinants of survival following the diagnosis of esophageal adenocarcinoma (United States). Cancer Causes Control 1996;7:322-7.
7. Jenkins GJS, Doak SH, Parry JM, et al. Barrett's metaplasia: the genetic pathways involved in its progression to adenocarcinoma. Br J Surg 2002;89:824-38.
8. Jankowski JA, Wright NA, Meltzer SJ, et al. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol 1999;154:965-73.
9. Fitzgerald RC, Triadafilopoulos G. Recent developments in the molecular characterization of Barrett's esophagus. Dig Dis 1998;16:63-80.
10. Montgomery E, Goldblum JR, Greenson JK, et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: A follow up study based on 138 cases from a diagnostic variability study. Hum Pathol 2001; 32:379-88.
11. Edwards MJ, Gable DR, Lentsch AB, et al. The rationale for esophagectomy as the optimal therapy for Barrett's esophagus with high-grade dysplasia. Ann Surg 1996;223:585-9.
12. Spechler SJ. Barrett's esophagus: an overrated risk factor. Gastroenterology 2000;119:587-9.
13. Macdonald CE, Wicks AC, Playford RJ. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: Observational study. BMJ 2000;321:1252-5.
14. Van der Burgh A, Dees J, Hop WCJ, et al. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996;39:5-8.
15. Hulscher JBF, Haringsma J, Benraadt J, et al. Comprehensive cancer centre Amsterdam Barrett advisory committee: first results. Neth J Med 2001;58:3-8.
16. Croft J, Parry EM, Jenkins GJS, et al. Analysis of the premalignant stages of Barrett's oesophagus through to adenocarcinoma by comparative genomic hybridisation. Eur J Gastroenterol Hepatol 2002;14:1179-86.
17. Ramirez MJ, Surralles J, Galofre P, et al. FISH analysis of 1 cen-1q12 breakage, chromosome 1 numerical abnormalities and centromeric content of micronuclei in buccal cells from thyroid cancer and hyperthyroidism patients treated with radioactive iodine. Mutagenesis 1999;14:121-7.
18. Debiec-Rychter M, Lasota J, Sarlomo-Rikala M, et al. Chromosomal aberrations in malignant gastrointestinal stromal tumors: correlation with c-KIT gene mutation. Cancer Genet Cytogenet 2001;128:24-30.
19. Huang S-F, Hsu H-C, Fletcher JA. Investigation of chromosomal aberrations in hepatocellular carcinoma by fluorescence in situ hybridisation. Cancer Genet Cytogenet 1999;111:21-7.
20. Geisinger KR. Endoscopic biopsies and cytologic brushings of the esophagus are diagnostically complementary. Am J Clin Pathol 1995;103:295-9.
21. Tsai TT, Bongiorno PF, Orringer MB, et al. Detection on p53 nuclear protein accumulation in brushings and biopsies of Barrett's esophagus. Cancer Detect Prey 1997;21:326-31.
22. Wang HH, Sovie S, Zeroogian JM, et al. Value of cytology in detecting intestinal metaplasia and associated dysplasia at the gastroesophageal junction. Hum Pathol 1997;28:465-71.
23. Falk GW, Chittajallu R, Goldblum JR, et al. Surveillance of patients with Barrett's esophagus for dysplasia and cancer with balloon cytology. Gastroenterol 1997;112:1787-97.
24. Reid BJ, Levine DS, Longton G, et al. Predictors of progression to cancer in Barrett's esophagus: Baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000;95:1669-76.
25. Riegman PHJ, Vissers KJ, Alers JC, et al. Genomic alterations in malignant transformation of Barrett's esophagus. Cancer Res 2001;61:3164-70.
26. Van Dekken H, Vissers CJ, Tilanus HW, et al. Clonal analysis of a case of multifocal oesophageal (Barrett's) adenocarcinoma by comparative genome hybridisation. J Pathol 1999;188:263-6.
27. Persons DL, Croughan WS, Borelli KA, et al. Interphase cytogenetics of esophageal adenocarcinoma and precursor lesions. Cancer Genet Cytogenet 1998;106:11-17.
28. Moskaluk CA, Hu J, Perlman EJ. Comparative genomic hybridisation of esophageal and gastroesophageal adenocarcinomas shows consensus areas of DNA gain and loss. Genes Chromosomes Cancer 1998;22:305-11.
29. Walch AK, Zitzelsberger HF, Bruch J, et al. Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence. Am J Pathol 2000;156:555-66.
30. Tselepis C, Morris CD, Wakelin D, et al. Upregulation of the oncogene c-myc in Barrett's adenocarcinoma: induction of c-myc by acidified bile acid in vitro. Gut 2003;52:174-80.
31. Coggi G, Bosari S, Roncalli M, et al. p53 protein accumulation and p53 gene mutation in esophageal carcinoma. Cancer 1997;79:425-32.
32. Coppola D, Schreiber RH, Mora L, et al. Significance of Fas and retinoblastoma protein expression during the progression of Barrett's metaplasia to adenocarcinoma. Ann Surg Oncol 1999;6:298-304.
33. Menke-Pluymers MBE, Van Drunen E, Vissers KJ, et al. Cytogenetic analysis of Barrett's mucosa and adenocarcinoma of the distal esophagus and cardia. Cancer Genet Cytogenet 1996;90:109-17.
34. Barrett MT, Sanchez CA, Prevo LJ, et al. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 1999;22:106-9